Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology. The associated price target remains the same with $40.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kura Oncology’s potential for growth and market penetration. The recent inclusion of KOMZIFTI in the National Comprehensive Cancer Network (NCCN) Guidelines as a Category 2A recommended treatment option is a significant endorsement that is expected to accelerate its adoption among healthcare providers. This rapid inclusion underscores the drug’s potential impact as the first and only once-daily targeted therapy approved for relapsed or refractory NPM1-m AML, a patient group with limited treatment options.
Furthermore, KOMZIFTI’s competitive advantages over other menin inhibitors, such as its strong efficacy, simpler dosing regimen, and favorable safety profile, position it well in the market. The anticipated milestone payment from Kyowa Kirin, following the drug’s approval, further strengthens Kura Oncology’s financial standing. These factors collectively contribute to Pantginis’s optimistic outlook on Kura Oncology’s stock, supporting his Buy recommendation.
In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $28.00 price target.